75434-63-8

Usage

Uses

Used in Organic Synthesis:
Tetrahydro-2H-pyran-2-ylmethyl 4-methylbenzenesulfonate is used as a protecting group to block the reactivity of certain functional groups, such as alcohols and amines, and to prevent unwanted reactions during chemical manipulations.
Used in Pharmaceutical Industry:
Tetrahydro-2H-pyran-2-ylmethyl 4-methylbenzenesulfonate is utilized in the preparation of various pharmaceuticals, contributing to the development of new drugs and improving the synthesis process.
Used in Agrochemical Industry:
Tetrahydro-2H-pyran-2-ylmethyl 4-methylbenzenesulfonate is also used in the preparation of agrochemicals, playing a role in the development of pesticides and other agricultural chemicals to enhance crop protection and productivity.
Used in Fine Chemicals Industry:
Tetrahydro-2H-pyran-2-ylmethyl 4-methylbenzenesulfonate is employed in the synthesis of various fine chemicals, which are important for a range of applications, including fragrances, dyes, and other specialty chemicals.

Upstream product

• 100-72-1 Tetrahydropyran-2-methanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 

Downstream Products

• 1431871-65-6 C₂₅H₂₇FN₆O₃ 
• 1431871-59-8 C₂₅H₂₈N₆O₃ 
• 1431871-60-1 C₂₅H₂₈N₆O₃ 
• 1217422-73-5 N-[(2Z)-5-tert-butyl-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3,4-thiadiazol-2(3H)-ylidene]-2-fluoro-5-(trifluoromethyl)benzamide 
• 75394-84-2 (+/-)-2-perhydro-2H-pyran-2-ylethanenitrile 

Relevant academic research and scientific papers

ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4

Disclosed herein are 2,3,5-trifluorophenyl-pyridazine substituted hexahydro-1H- cyclopenta[c]pyrrole compounds, useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4

Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER

Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4

Disclosed herein are substituted hexahydro-l//-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Structure-activity relationship studies of (E)-3,4-dihydroxystyryl alkyl sulfones as novel neuroprotective agents based on improved antioxidant, anti-inflammatory activities and BBB permeability

(E)-3,4-dihydroxystyryl alkyl sulfones, as new analogues of neurodegenerative agents, were designed and synthesized. The biological results demonstrated that most of the target compounds preserved antioxidant and anti-inflammatory potency in scavenging reactive free radicals, protecting neuronal cells against neurotoxins such as H2O2, 6-hydroxydopamine and inhibiting lipopolysaccharide (LPS)-induced over-production of NO. Among these compounds, 6.22 with cyclopentyl propyl exhibited prominent antioxidant activity at low concentration (2.5 μM) in H2O2 model (cell viability = 94.5%). In addition, 6.22 (IC50 = 1.6 μM) displayed better anti-inflammatory activity than that of lead compound 1 (IC50 = 13.4 μM). In view of the outstanding performance of 6.22, the apoptotic rates of H2O2-damaged PC12 cells were detected by Annexin V-FITC/PI assay. 6.22 showed higher potency in inhibition of apoptosis than 1 at low concentration (2.5 μM), consisting with the antioxidant and anti-inflammatory models. Furthermore, with the predicted CNS (+) blood-brain barrier (BBB) permeability (Pe = 6.84 × 10?6 cm s?1), low cytotoxicity and favorable physiochemical properties based on calculation, compound 6.22 can be further developed as a potential multifunctional neuroprotective agent.

Palladium-Catalyzed Atom-Transfer Radical Cyclization at Remote Unactivated C(sp3)?H Sites: Hydrogen-Atom Transfer of Hybrid Vinyl Palladium Radical Intermediates

A novel mild, visible-light-induced palladium-catalyzed hydrogen atom translocation/atom-transfer radical cyclization (HAT/ATRC) cascade has been developed. This protocol involves a 1,5-HAT process of previously unknown hybrid vinyl palladium radical intermediates, thus leading to iodomethyl carbo- and heterocyclic structures.

NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES

The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.